Because the mTORC1/S6K1 pathway is critical for the regulation of autophagy in AML initiation and progression, mTORC1/S6K1 inhibitors, such as RapaLink-1, show therapeutic potential for drug-resistant AML [170]. The gene discussed is RPS6KB1; the disease is acute myeloid leukemia.